Navigation Links
MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Date:10/21/2010

MOUNTAIN VIEW, Calif., Oct 21 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Thomas P. McCracken as Vice President, Intellectual Property. Mr. McCracken will lead the company's intellectual property program in support of the potential commercialization of the company's lead product candidate, LEVADEX™ orally inhaled migraine therapy, and other product opportunities.

Mr. McCracken has extensive legal experience within the healthcare industry. Most recently, Mr. McCracken was Vice President and Chief Patent Counsel at Durect Corporation, where he was responsible for management, development and creation of all intellectual property assets.  He was previously with PowderJect Pharmaceuticals, where he was responsible for managing IP assets and services across all research and development functions of the company, including vaccines, biopharmaceuticals and medical devices.   Prior to PowderJect, Mr. McCracken was in private patent law practice and specialized in the areas of pharmaceuticals, biotechnology, biomedical engineering and medical devices. His knowledge of the biotechnology field is further supplemented with several years of technical experience in research and development at privately held biopharmaceutical companies, including research activities at the Research Institute of Scripps Clinic.

"Tom joins the company at an ideal time, as his expertise in patent and trademark planning, patent claims structuring and technology licensing will benefit us as we prepare for the potential commercialization of LEVADEX and develop other potential pipeline products," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

Mr. McCracken holds a Bachelor's degree in Microbiology from the University of California, San Diego and a Juris Doctor degree from Santa Clara Unive
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Global Cardiac ... http://www.reportlinker.com/p0240523/Global-Cardiac-Monitoring-Systems-Market-2009-2013.html With advancements in technology, ... capabilities have been introduced in the Cardiac Monitoring ...
... 2011 Reportlinker.com announces that a new market ... Hepatitis A Preventive Vaccines - Pipeline ... http://www.reportlinker.com/p0453473/Hepatitis-A-Preventive-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Hepatitis A ... to 2017 SummaryGlobalData, the industry ...
Cached Medicine Technology:Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 2Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 3Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
(Date:4/23/2014)... prevent the depletion of self-control, according to research published ... Association for Psychological Science. , Self-control can be difficult ... attention on a boring textbook are hard things to ... difficulty: Exerting self-control for a long period seems to ... tasks. , "It is as if self-control is a ...
(Date:4/22/2014)... been shown to reduce seizures in patients with medication-resistant ... with an innovative electrode placement planning system developed by ... of seizures in nearly half of the implanted Rush ... good news for a large portion of the nearly ... seizures can,t be controlled with medications and who are ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... age had an increased risk of developing high blood ... Johansson, Karolinska Institute, Stockholm reported in the Journal Circulation ... prone to high blood pressure compared to normal born ... data from 329,495 Swedish men born between 1973 and ...
... study, published in the November issue of the Journal ... in residential care can reduce their incidence of falls ... years.// ,To determine whether vitamin D supplementation can ... people in residential care who are not classically vitamin ...
... as Kyolic may decrease the risk of heart attacks ... UK scientists.// ,Dr. Khalid Rhaman and colleagues from ... of Kyolic brand aged garlic extract inhibits platelet aggregation ... clots. Clot formation inside healthy blood vessels is abnormal ...
... under 50 are more likely to die from suicide than ... // ,A study of public hospital emergency departments in ... attending the emergency departments of seven Perth hospitals between June ... committed suicide within weeks of being discharged. The sample included ...
... living organisms, are exposed to ever-changing environments, oxidative ... able to defend themselves against all these insults, ... abilities simply by ‘stealing’ genetic information from other ... of sex, known as horizontal gene transfer. ...
... (CBI) carried out simultaneous raids on some government hospital ... cities on Monday.// ,The raids were conducted in ... official of the investigating agency said., ,The houses ... and Uma Goel of Sucheta Kriplani Hospital here were ...
Cached Medicine News:Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
Auto Refkeratomoeter...
... The InfusO.R. Pump is a ... aid in the administration of ... anesthetic procedures. It provides for ... muscle relaxants, and vasoactive drugs ...
Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: